Roth David 4
4 · Syros Pharmaceuticals, Inc. · Filed Dec 8, 2023
Insider Transaction Report
Form 4
Roth David
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-12-06$3.95/sh−6,287$24,834→ 6,287 total
Footnotes (1)
- [F1]The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.